Ager Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
AGER encodes RAGE (Receptor for Advanced Glycation End Products), a pattern recognition receptor involved in inflammation and neurodegeneration.
| Property |
Value |
| Gene Symbol |
AGER |
| Protein Name |
RAGE |
| Chromosome |
6p21.3 |
| UniProt ID |
Q15120 |
| NCBI Gene ID |
177 |
| OMIM |
600841 |
RAGE is a multi-ligand receptor that binds:
- Advanced glycation end products (AGEs)
- HMGB1 (High Mobility Group Box 1)
- S100B protein
- Amyloid-beta fibrils
- DNA release from damaged cells
- NF-κB activation → pro-inflammatory cytokine production
- MAPK activation → cellular stress response
- RAGE-DIAPH1 → cytoskeletal reorganization
- Oxidative stress generation via NADPH oxidase
- RAGE mediates Aβ-induced neuroinflammation
- Elevated RAGE expression in AD brain
- RAGE-Aβ interaction enhances neuronal toxicity
- Therapeutic target: RAGE inhibitors in development
- RAGE involved in dopaminergic neuron death
- Links alpha-synuclein pathology to inflammation
- Elevated in substantia nigra of PD patients
- HMGB1-RAGE signaling in motor neuron disease
- Contributes to neuroinflammation
| Approach |
Status |
| Anti-RAGE antibodies |
Preclinical |
| RAGE inhibitors |
Phase 2 trials |
| Decoy receptors |
Research |
- Stern D, et al. (2002) "RAGE: a novel target for drug intervention in diabetic complications.*" Current Opinion in Investigational Drugs. PMID:12502350
- Srikanth V, et al. (2011) "Role of advanced glycation end products (RAGE) in the brain and its implications for Alzheimer's disease." Journal of Alzheimer's Disease. PMID:21593570
- Casserly I, Topol E (2004) "Convergence of atherosclerosis and Alzheimer's disease: inflammation as a common pathway." Lancet. PMID:15531297
- Liu R, Gao F, et al. (2021) "RAGE mediates Aβ-induced tau pathology and synaptic dysfunction." Acta Neuropathologica Communications. PMID:33910657
- Chen X, et al. (2019) "Targeting RAGE as a therapeutic strategy for neurodegenerative diseases." Drug Discovery Today. PMID:31734362
The RAGE receptor exists in multiple isoforms:
| Isoform |
Description |
Expression |
| Full-length RAGE |
Membrane-bound, signaling competent |
Various tissues |
| Soluble RAGE (sRAGE) |
Decoy receptor, secreted |
Detectable in plasma/CSF |
| N-truncated RAGE |
Lacks transmembrane domain |
Alternative splicing |
The extracellular domain contains one V-type (variable) domain and two C-type (constant) domains, responsible for ligand binding.
¶ Ligand Binding and Activation Mechanisms
RAGE activates multiple downstream signaling cascades:
- NF-κB pathway: Leads to transcription of pro-inflammatory genes
- MAPK pathways: ERK, JNK, and p38 MAPKs are activated
- PI3K/Akt pathway: Cell survival and proliferation signals
- Rho GTPases: Cytoskeletal dynamics via RAGE-DIAPH1 interaction
¶ Genetic Variants and Disease Risk
Several AGER polymorphisms have been associated with disease risk:
- -374T/A polymorphism: Associated with reduced AD risk
- G82S polymorphism: Affects ligand binding affinity
- Promoter variants: Influence expression levels
RAGE-related biomarkers for neurodegenerative diseases:
- sRAGE levels: Lower in AD and PD patients
- HMGB1: Elevated in CSF of AD patients
- RAGE expression: Upregulated in affected brain regions
The study of Ager Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Stern D, et al. (2002) "RAGE: a novel target for drug intervention." Current Opinion in Investigational Drugs. PMID:12502350
- Srikanth V, et al. (2011) "RAGE and Alzheimer's disease." Journal of Alzheimer's Disease. PMID:21593570
- Casserly I, Topol E (2004) "Convergence of atherosclerosis and Alzheimer's disease." Lancet. PMID:15531297